Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease - PubMed (original) (raw)
. 1993 Feb 15;268(5):3072-83.
Affiliations
- PMID: 8428986
Free article
Structural alterations in the peptide backbone of beta-amyloid core protein may account for its deposition and stability in Alzheimer's disease
A E Roher et al. J Biol Chem. 1993.
Free article
Abstract
The structure of beta-amyloid (beta A) from Alzheimer disease brains was examined to determine if post-translational modifications might be linked to the abnormal deposition of this peptide in the diseased tissue. The beta A peptides were isolated from the compact amyloid cores of neuritic plaques and separated from minor glycoprotein components by size-exclusion high-pressure liquid chromatography (HPLC). This parenchymal beta A has a maximal length of 42 residues, but shorter forms with "ragged" NH2 termini are also present. Tryptic peptide analysis revealed heterogeneity in the beta A1-5 and beta A6-16 peptides, each of which eluted as four peaks on reverse phase HPLC. Amino acid composition and sequence analyses, mass spectrometry, enzymatic methylation, and stereoisomer determinations revealed that these multiple peptide forms resulted from structural rearrangements of the aspartyl residues at beta A positions 1 and 7. The L-isoaspartyl form predominates at each of these positions, whereas the D-isoaspartyl, L-aspartyl, and D-aspartyl forms are present in lesser amounts. beta A purified from the leptomeningeal microvasculature contains the same structural alterations as parenchymal beta A, but is 2 residues shorter at its COOH terminus. Using two different purification protocols, and using a synthetic beta A1-42 peptide as a control, we show that these modifications arose endogenously and were not caused by the experimental manipulations. The abundance of structurally altered aspartyl residues may profoundly affect the conformation of the beta A protein within plaque cores and thus significantly impact normal catabolic processes designed to limit its deposition. These alterations may therefore contribute to the production and stability of beta-amyloid deposits in Alzheimer brain tissue.
Similar articles
- Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease.
Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP, Ball MJ. Gowing E, et al. J Biol Chem. 1994 Apr 15;269(15):10987-90. J Biol Chem. 1994. PMID: 8157623 - beta-Amyloid-(1-42) is a major component of cerebrovascular amyloid deposits: implications for the pathology of Alzheimer disease.
Roher AE, Lowenson JD, Clarke S, Woods AS, Cotter RJ, Gowing E, Ball MJ. Roher AE, et al. Proc Natl Acad Sci U S A. 1993 Nov 15;90(22):10836-40. doi: 10.1073/pnas.90.22.10836. Proc Natl Acad Sci U S A. 1993. PMID: 8248178 Free PMC article. - Comparative analysis of amyloid-beta chemical structure and amyloid plaque morphology of transgenic mouse and Alzheimer's disease brains.
Kuo YM, Kokjohn TA, Beach TG, Sue LI, Brune D, Lopez JC, Kalback WM, Abramowski D, Sturchler-Pierrat C, Staufenbiel M, Roher AE. Kuo YM, et al. J Biol Chem. 2001 Apr 20;276(16):12991-8. doi: 10.1074/jbc.M007859200. Epub 2001 Jan 10. J Biol Chem. 2001. PMID: 11152675 - Biological significance of isoaspartate and its repair system.
Shimizu T, Matsuoka Y, Shirasawa T. Shimizu T, et al. Biol Pharm Bull. 2005 Sep;28(9):1590-6. doi: 10.1248/bpb.28.1590. Biol Pharm Bull. 2005. PMID: 16141521 Review. - Brain parenchymal and microvascular amyloid in Alzheimer's disease.
Vinters HV, Wang ZZ, Secor DL. Vinters HV, et al. Brain Pathol. 1996 Apr;6(2):179-95. doi: 10.1111/j.1750-3639.1996.tb00799.x. Brain Pathol. 1996. PMID: 8737932 Review.
Cited by
- Serine phosphorylation mimics of Aβ form distinct, non-cross-seeding fibril morphs.
Sanagavarapu K, Meisl G, Lattanzi V, Bernfur K, Frohm B, Olsson U, Knowles TPJ, Malmendal A, Linse S. Sanagavarapu K, et al. Chem Sci. 2024 Oct 11;15(45):19142-59. doi: 10.1039/d3sc06343g. Online ahead of print. Chem Sci. 2024. PMID: 39494375 Free PMC article. - Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease.
Masters CL, Selkoe DJ. Masters CL, et al. Cold Spring Harb Perspect Med. 2012 Jun;2(6):a006262. doi: 10.1101/cshperspect.a006262. Cold Spring Harb Perspect Med. 2012. PMID: 22675658 Free PMC article. Review. - Generation of a recombinant Fab antibody reactive with the Alzheimer's disease-related Abeta peptide.
Tammer AH, Coia G, Cappai R, Fuller S, Masters CL, Hudson P, Underwood JR. Tammer AH, et al. Clin Exp Immunol. 2002 Sep;129(3):453-63. doi: 10.1046/j.1365-2249.2002.01905.x. Clin Exp Immunol. 2002. PMID: 12197886 Free PMC article. - Transgenic mouse models of Alzheimer's disease and amyotrophic lateral sclerosis.
Borchelt DR, Wong PC, Sisodia SS, Price DL. Borchelt DR, et al. Brain Pathol. 1998 Oct;8(4):735-57. doi: 10.1111/j.1750-3639.1998.tb00198.x. Brain Pathol. 1998. PMID: 9804381 Free PMC article. Review. - Truncated and modified amyloid-beta species.
Kummer MP, Heneka MT. Kummer MP, et al. Alzheimers Res Ther. 2014 May 26;6(3):28. doi: 10.1186/alzrt258. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 25031638 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical